Corporacio Sanitaria Parc Tauli

Sabadell(Barcelona) 08208

0 studies enrolling now · 2 studies all time

What they study most

BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Neoplasms, Prostate Cancer

Studies at this site

• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer — Completed